We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease.
- Authors
Ho Cheol Kim; Jung Su Lee; Sang Hyung Kim; Hoon Sub So; Chang Yoon Woo; Jae Lyun Lee
- Abstract
Von Hippel-Lindau (VHL) disease is an autosomal dominant disease that produces a variety of tumors and cysts in the central nervous system and visceral organs, including renal cell carcinoma (RCC). RCC in patients with VHL disease does not frequently metastasize, therefore, the response to treatment and prognosis of metastatic RCC developed in patients with VHL disease has not been reported. Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Here, we report on four patients with metastatic RCC in VHL disease who received sunitinib and achieved partial responses that have lasted for a prolonged period of time.
- Subjects
CANCER treatment; RENAL cell carcinoma; PROTEIN-tyrosine kinase inhibitors; VON Hippel-Lindau disease; ANTINEOPLASTIC agents; DRUG efficacy; THERAPEUTICS
- Publication
Cancer Research & Treatment, 2013, Vol 45, Issue 4, p349
- ISSN
1598-2998
- Publication type
Article
- DOI
10.4143/crt.2013.45.4.349